High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma

Cumulative response to DLI and incidence of GVHD. A, Time taken to maximal response (CR or full donor chimerism) after DLI administered for progressive disease (solid line) or MC (dashed line). B, Cumulative incidence of extensive chronic (solid line) and acute grade II-IV GVHD. The numbers below the figures indicate the number of patients at risk at each time point.

Survival after DLI in patients treated for relapsed/progressive disease; overall (- - - -) and progression-free (——) survival after the most recent DLI given for disease progression. Progression-free survival includes all patients in stable CR at the time the data were evaluated. This figure should be interpreted together with Figure 3, which indicates the timing and dose of DLI in individual patients.

Timing of DLI and response to treatment by patient. The horizontal bars represent the time elapsed since transplantation for each patient, colored to indicate the response to DLI by indication (MC or disease progression). Abbreviations are explained in Table 2.

Relationship between DLI dose and incidence of GVHD. Each circle represents the administration of a single dose of donor lymphocytes. Black circles indicate the occurrence of acute grade II-IV or extensive chronic GVHD; open circles indicate that GVHD did not occur. Five doses of donor lymphocytes were not evaluable for GVHD (not shown).